These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33078980)

  • 1. A T-cell-dependent antibody response study using a murine surrogate anti-PD-1 monoclonal antibody as an alternative to a non-human primate model.
    Plitnick LM; Hutchins B; Dubey S; Li N; Amin RP; Born S; Mangadu R; Phillips JH; Sriram V; Herzyk DJ
    J Immunotoxicol; 2020 Dec; 17(1):175-185. PubMed ID: 33078980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biophysical and Immunological Characterization and
    Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A
    Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy.
    Li F; Li J; Yin K; Zhang J; Li ZH; Lu L; Bao YW; Qin Z; Zheng Y; Yang BT; Li J; Wang X
    Acta Pharmacol Sin; 2021 Jan; 42(1):142-148. PubMed ID: 32467569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models.
    Georgiev P; Muise ES; Linn DE; Hinton MC; Wang Y; Cai M; Cadzow L; Wilson DC; Sukumar S; Caniga M; Chen L; Xiao H; Yearley JH; Sriram V; Nebozhyn M; Sathe M; Blumenschein WM; Kerr KS; Hirsch HA; Javaid S; Olow AK; Moy LY; Chiang DY; Loboda A; Cristescu R; Sadekova S; Long BJ; McClanahan TK; Pinheiro EM
    Mol Cancer Ther; 2022 Mar; 21(3):427-439. PubMed ID: 34965960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
    Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
    MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors.
    Damsky W; Jilaveanu L; Turner N; Perry C; Zito C; Tomayko M; Leventhal J; Herold K; Meffre E; Bosenberg M; Kluger HM
    J Immunother Cancer; 2019 Jun; 7(1):153. PubMed ID: 31200747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study.
    Gane E; Verdon DJ; Brooks AE; Gaggar A; Nguyen AH; Subramanian GM; Schwabe C; Dunbar PR
    J Hepatol; 2019 Nov; 71(5):900-907. PubMed ID: 31306680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
    Schofield DJ; Percival-Alwyn J; Rytelewski M; Hood J; Rothstein R; Wetzel L; McGlinchey K; Adjei G; Watkins A; Machiesky L; Chen W; Andrews J; Groves M; Morrow M; Stewart RA; Leinster A; Wilkinson RW; Hammond SA; Luheshi N; Dobson C; Oberst M
    MAbs; 2021; 13(1):1857100. PubMed ID: 33397194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy.
    Kim HM; Kim KJ; Lee K; Yoon MJ; Choih J; Hong TJ; Cho EJ; Jung HJ; Kim J; Park JS; Na HY; Heo YS; Park CG; Park H; Han S; Bae D
    BMC Immunol; 2024 May; 25(1):29. PubMed ID: 38730320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
    Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
    J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice.
    Yu D; Liu H; Shi S; Dong L; Wang H; Wu N; Gao H; Cheng Z; Zheng Q; Cai J; Zou L; Zou Z
    Immunol Lett; 2015 Dec; 168(2):293-9. PubMed ID: 26475398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation.
    Wang M; Wang J; Wang R; Jiao S; Wang S; Zhang J; Zhang M
    Commun Biol; 2019; 2():392. PubMed ID: 31667366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.
    Wang X; Dong A; Xiao J; Zhou X; Mi H; Xu H; Zhang J; Wang B
    Cell Mol Immunol; 2016 Nov; 13(6):850-861. PubMed ID: 26166767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2015 Jan; 51(1):7-20. PubMed ID: 25685857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diverse immune responses to HBV surface epitope variants after vaccine booster in adolescents immunized in infancy.
    Lai MW; Liang KH; Yeh CT
    Clin Microbiol Infect; 2019 Sep; 25(9):1140-1146. PubMed ID: 30771531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human
    Burova E; Hermann A; Waite J; Potocky T; Lai V; Hong S; Liu M; Allbritton O; Woodruff A; Wu Q; D'Orvilliers A; Garnova E; Rafique A; Poueymirou W; Martin J; Huang T; Skokos D; Kantrowitz J; Popke J; Mohrs M; MacDonald D; Ioffe E; Olson W; Lowy I; Murphy A; Thurston G
    Mol Cancer Ther; 2017 May; 16(5):861-870. PubMed ID: 28265006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
    Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
    J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
    Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
    Front Immunol; 2020; 11():895. PubMed ID: 32528470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
    Leroux-Roels G; Van Belle P; Vandepapeliere P; Horsmans Y; Janssens M; Carletti I; Garçon N; Wettendorff M; Van Mechelen M
    Vaccine; 2015 Feb; 33(8):1084-91. PubMed ID: 25444781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.